• Notifications
    This feature only available to registered users.
  • Alerts
    This feature only available to registered users
  • Welcome Guest!
  • Login Signup

Stock [ BUY ] / [ SELL ] Trading Strategies
. [ Show Details ]


Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





NO
     
DRRX [ Durect Corp ]
Last Trade 2.33 Date 8/6/2020
Change % 0.65 % Price Change 0.02
Open 2.29 52 Week High 3.949
High 2.39 52 Week Low 0.9502
Low 2.25 Type stock
Volume 1815794 Average Volume 1606881
Prev Close 2.315 Stock Exchange NASDAQ
Bid 2.31 Ask 2.38
Bid Size 1 Ask Size 49
1st Yr Estimated EPS Growth 6.0 2nd Yr Estimated EPS Growth 2.1429
2 Years Forward Earning Yield -0.095 2 Years Forward PE Ratio
2 Years EV/Forward EBIT 2 Years EV/Forward EBITDA
Book Value per Share 0.1854 Book Value Yield 0.0801
Buy Back Yield CAPE Ratio
Cash Return 0.0141 Cash Flow per Share 0.0195
Cash Flow Yield 0.0084 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield -0.0043 EV/EBIT 778.7494
EV/EBITDA 778.7494 EV / Free Cash Flow 116.8867
EV / Forward EBIT EV / Forward EBITDA
EV / Forward Revenue 10.7718 EV / Pre Tax Income
EV / Revenue 8.5703 EV / Total Asset 5.8971
Expected Dividend Growth Rate Free Cash Flow per Share 0.0184
Free Caash Flow Ratio 125.800795 Free Cash Flow Yield 0.0079
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield -0.0302 Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio Payout Ratio 0.0
PB Ratio 12.486846 PB Ratio 10 Year Growth 0.017253
PB Ratio 3 Year Growth 13.496126 Cash Ratio 3 Year Average 587.7427
Price to Cash Flow Ratio 118.505189 PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average 5.187642 PE Ratio 10 Year Growth
PE Ratio 10 Year High 8.722222 PE Ratio 10 Year Low 3.305238
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg
PE Ratio 5 Year Avg PE Ratio 5 Year High
PE Ratio 5 Year Low Free Cash Flow Ratio 10 Year Growth 0.122031
Free Cash Flow Ratio 3 Year Avg 229.61885 Price Change 1 Month 1.181122
Price to Cash Ratio 8.872753 Price / EBITDA 838.139238
Price to Sales Ratio 9.223934 Price to Sales Ratio 10 Year Growth 0.020237
Price to Sales Ratio 3 Year Avg 8.760854 Price to Sales Ratio 5 Year Avg
Sale per Share 0.251 Sales Yield 0.1084
Sustainable Growth Rate -0.0618 Tangible Book Value per Share 0.1528
Tangible Book Value per Share 3 year Avg 0.0752 Tangible Book Value per Share 5 year Avg 0.0721
Total Asset per Share 0.3712 Total Yield
Working Capital per Share 0.2537 Working Capital per Share 3 Year Avg 0.1649
Working Capital per Share 5 Year Avg 0.192 Beta 1.688293
Company Profile

DURECT Corporation focuses on the development of pharmaceutical products for pain, central nervous system disorders, cardiovascular disease, and other chronic diseases based on its proprietary drug formulations and delivery platform technologies. Its products include Remoxy, an oxycodone gelatin capsule for chronic pain, which is accepted as a new drug application; POSIDUR, a release formulation of bupivacaine that is under Phase III clinical trial for post operative pain; ELADUR, a transdermal bupivacaine patch, which is under Phase II clinical trial, provides continuous delivery of bupivacaine for up to three days from a single application, as well as for the treatment of pain associated with post-herpetic neuralgia; and TRANSDUR-Sufentanil, a proprietary transdermal sufentanil patch, which is under Phase II clinical trial, provides continuous delivery of sufentanil for a period of up to seven days from a single application. The company?s products also comprise oral controlled release opioid for pain that is under the Phase I clinical trial; and ORADUR-ADHD, a preclinical trial product targeting attention deficit hyperactivity disorder. It markets ALZET, the miniature implantable osmotic pumps and accessories for experimental research in mice, rats, and other laboratory animals. The company also develops and manufactures various biodegradable polymers based on lactide, glycolide, and caprolactone under the LACTEL brand for pharmaceutical and medical device clients, as well as conducts research and development of pharmaceutical products in collaboration with third party pharmaceutical and biotechnology companies. The company has strategic agreements with Alpharma Ireland Limited; Nycomed Danmark, ApS; Pain Therapeutics, Inc.; Endo Pharmaceuticals Inc; Curaxis Pharmaceutical Corporation; ALZA Corporation; EpiCept Corporation; NeuroSystec Corporation; and King Pharmaceuticals, Inc. DURECT Corporation was founded in 1998 and is based in Cupertino, California.